RARenata Abrahão

Renata Abrahão

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Renata Abrahão has a total of 157 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Burden of Hospitalizations in Four Adolescent and Young Adult Cancer Survivor Populations in the United States, 2006 to 2020

    by Karen J. Wernli, Eric C. Haupt, Andrew B. Smitherman, Thearis Osuji, Ernest Shen, Neetu Chawla, Mallory Casperson, Anne C. Kirchhoff, Cecile A. Laurent, Kathryn J. Ruddy, et al.

    Background: We describe hospitalization rates in adolescent and young adult (AYA) cancer survivors 2 to 5 years (Y2–Y5) from diagnosis. Methods: Observational study of AYA cancer survivors diagnosed 2006 to 2020 was conducted in two healthcare systems [Kaiser Permanente Southern California (KPSC; n = 7,889) and Kaiser Permanente Northern California (KPNC; n = 7,338)] and two states [California (47,302) and Utah (n = 7,935)]. Hospitalizations were ascertained from electronic health records and statewide administrative records and stratified into pregnancy-related and other indications. Hospitalization rates were calculated by cohort. We estimated patient factors associated with hospitalizations using a Poisson model. Results: Most AYA survivors were women (∼64% of all cohorts), with a mean age of ∼31 years at diagnosis, and were predominantly non-Hispanic White (range, 35.1%–81.2%) or Hispanic (range, 14.3%–40.6%). Overall, 21% to 24% of AYA survivors experienced ≥1 hospitalization. Unadjusted hospitalization rates declined from Y2 [range, 155.1–243.4 per 1,000 person-years (PY)] to Y5 (range, 105.8–132.0 PY; P trend < 0.0001 in all cohorts). Factors associated with increased non–pregnancy-related hospitalizations were [range of relative risks (RR)] non-Hispanic Black race/ethnicity (RR, 1.46–1.66 vs. non-Hispanic White); public insurance (RR, 1.57–1.93 vs. commercial/military); receipt of chemotherapy (RR, 1.51–1.81); and cancer type—breast cancer (RR, 1.69–1.97), cervical cancer (RR, 2.30–3.31), colorectal cancer (RR, 2.76–3.66), acute lymphoblastic leukemia (ALL; RR, 2.89–5.19), acute myeloid leukemia (AML; RR, 2.11–5.05), and sarcoma (RR, 2.70–4.96; all vs. thyroid). Conclusions: Although hospitalizations decline as the time from diagnosis elapses across health system settings and states, nearly one in five AYA cancer survivors experience hospitalization in early survivorship. Impact: Hospitalization rates remain elevated in some AYA patient subgroups in early survivorship, highlighting the need to identify AYAs at risk to mitigate unanticipated hospitalizations and costs.

  • Transitions Within and Use of Outpatient Primary and Oncology Care in Survivors of Adolescent and Young Adult-Onset Cancers

    by Erin E. Hahn, Eric C. Haupt, Neetu Chawla, Thearis A. Osuji, Ernest Shen, Andrew B. Smitherman, Mallory Casperson, Anne C. Kirchhoff, Bradley J. Zebrack, Cecile A. Laurent, et al.

    PURPOSE: Survivors of adolescent and young adult (AYA)-onset cancers require comprehensive cancer surveillance care. Guidelines recommend 1-4 clinician visits annually for 5 years depending on stage and disease. The goal of this study was to identify factors associated with patterns of post-treatment primary and oncology care in a large cohort of survivors of AYA-onset cancers diagnosed within an integrated health care system. METHODS: Patients diagnosed with cancer between 2006 and 2020 age 15-39 years were included. Surveillance visits were identified from electronic medical records 2-5 years after diagnosis. Multivariable logistic regression was used to assess associations with zero oncology specialty visits. RESULTS: Of 7,925 survivors, 46% were Hispanic, 6% non-Hispanic Black, 11% non-Hispanic Asian, 35% non-Hispanic White, and 65% female. One-quarter had no oncology specialty visits in the first surveillance year rising to 38% in year 5; 31% had 3+ visits in the first year, declining to 13% in year 5. Over the surveillance period, 17% did not have any oncology specialty visits and 6% had no primary care or oncology visits. Those who were male (odds ratio [OR], 1.21 [95% CI, 1.02 to 1.45]), 20-24 years at diagnosis (OR, 1.58, 95% CI, 1.27 to 1.9; v 35 to 39), or non-Hispanic Black (OR, 1.38, 95% CI, 1.05 to 1.82; v non-Hispanic White) or had high-deductible commercial or Medicaid insurance (OR, 1.35, 95% CI, 1.15 to 1.59; OR, 1.42, 95% CI, 1.11 to 1.82, respectively; v no or low deductible commercial) were more likely to be in the 0-visit group for oncology specialty care. CONCLUSION: Although the majority of this cohort received either primary or oncology specialty care, our study identifies those who may need tailored outreach for follow-up care. Continued research into development and testing of interventions to improve uptake of appropriate health care for survivors of AYA-onset cancers is critical.


  • Peripheral Neuropathy Incidence in Children, and Adolescents and Young Adults With Cancer and Medicaid Insurance in California

    by Renata Abrahão, Julianne J.P. Cooley, Justine M. Kahn, Ann Brunson, Elysia M. Alvarez, Anjlee Mahajan, Ted Wun, Rashmi Verma, Kathryn J. Ruddy, Theresa H.M. Keegan

    PURPOSE: Chemotherapy-induced peripheral neuropathy is a potentially debilitating adverse effect of cancer therapy that can lead to delay, reduction, or discontinuation of cancer treatment. Population-based data on peripheral neuropathy incidence among young cancer survivors are lacking. METHODS: Using a linkage between Medicaid, the California Cancer Registry, and hospitalization and emergency department data, we identified 6,028 adolescents and young adults (15-39 years) with Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), breast cancer, colorectal cancer, or testicular cancer and 418 children (v 6.2%) and paclitaxel for breast cancer (22.6% v 5.1%). In multivariable analysis, the agents most strongly associated with peripheral neuropathy were brentuximab (±other neurotoxic drugs) for HL (hazard ratio [HR], 9.53 [95% CI, 5.95 to 15.26]); brentuximab (±vinca alkaloids; HR, 7.00 [95% CI, 4.13 to 11.87]) for NHL, paclitaxel for breast cancer (HR, 4.03 [95% CI, 3.05 to 5.31]); oxaliplatin for colorectal cancer (HR, 3.46 [95% CI, 2.23 to 5.36]); and cisplatin and etoposide for testicular cancer (HR, 2.06 [95% CI, 1.37 to 3.11]). CONCLUSION: The high incidence of peripheral neuropathy highlights the need for frequent monitoring, new supportive care approaches, and development of novel therapeutic agents to minimize toxicity while maintaining treatment efficacy.


  • Open Access

    Table S1 from Cervical Cancer Stage at Diagnosis and Survival among Women ≥65 Years in California

    by Julianne J.P. Cooley, Frances B. Maguire, Cyllene R. Morris, Arti Parikh-Patel, Renata Abrahão, Hui A. Chen, Theresa H.M. Keegan

    Supplementary Table S1. Association between sociodemographic and clinical characteristics with late-stage (II-IV, Unknown*) cervical cancer diagnosis for patients ≥65 years, 2009-2018 (N=2,420)

  • Open Access

    Data from Cervical Cancer Stage at Diagnosis and Survival among Women ≥65 Years in California

    by Julianne J.P. Cooley, Frances B. Maguire, Cyllene R. Morris, Arti Parikh-Patel, Renata Abrahão, Hui A. Chen, Theresa H.M. Keegan

    Background:Through adequate screening and follow-up, cervical cancer can be prevented or detected at early-stage (stage I), which is related to excellent survival. Current guidelines recommend discontinuing screening for women ≥65 years with history of normal Pap and/or HPV tests, potentially leaving this age group vulnerable. This study examined late-stage disease in a population-based cohort.Methods:Using California Cancer Registry data, we identified 12,442 patients ages ≥21 years with a first primary cervical cancer diagnosed during 2009–2018. Proportions of late-stage disease (stages II–IV) and early- and late-stage 5-year relative survival are presented by the age group. Among patients ages ≥65 years, multivariable logistic regression estimated associations of sociodemographic and clinical characteristics with late-stage cervical cancer.Results:Nearly one fifth of patients (n = 2,171, 17.4%) were ≥65 years. More women ages ≥65 years (71%) presented with late-stage disease than younger women (48% in patients ages <65). Late-stage 5-year relative survival was lower for women ≥65 years (23.2%–36.8%) compared with patients <65 (41.5%–51.5%). Characteristics associated with late-stage cervical cancer in women ≥65 years included older age [odds ratio (OR), 1.02; 95% confidence interval (CI), 1.01–1.04; each year], non-adenocarcinoma histologic subtypes, and comorbidities (OR, 1.59; 95% CI, 1.21–2.08).Conclusions:There remains a significant burden of advanced cervical cancer in women ≥65.Impact:Efforts should be made to better understand how the current screening paradigm is failing women of 65 years and older. Future work should focus on determining past screening history, lapses in follow-up care, and non-invasive testing approaches.

  • Open Access

    Identifying clustering in patterns of late effects among survivors of adolescent and young adult Hodgkin lymphoma

    by Kellee Parker, Mallorie B Heneghan, Qian W Li, Ann Brunson, Judy Ou, Heydon K Kaddas, Renata Abrahão, Jessica Chubak, Karen J Wernli, Brad Zebrack, et al.

    Background: We examined late effects clustering among adolescent and young adult (AYA; age 15-39 years at diagnosis) Hodgkin lymphoma (HL) survivors and identified characteristics associated with each cluster. Methods: We included AYAs with HL in 2006-2018 from the California and Utah Cancer Registries linked to statewide hospitalization, emergency department, and ambulatory surgery visit data. We identified severe late effects >2 years after cancer diagnosis in 9 late effects categories. Latent class analysis (LCA) was used to identify late effects clusters. Multinomial logistic regression models estimated adjusted associations of demographic and treatment characteristics with LCA late effect group. Results: We identified 4635 AYA HL survivors with median follow-up of 8.2 years and 4 late effects groups: 77.1% had a low probability of any late effect (Low Morbidity), 12.8% had high probability of Thyroid disorders, 8.0% had high probability of Cardiovascular Disease (CVD), and 2.1% had high probability of Multiple Conditions (CVD, diabetes/pancreatic, thyroid, and renal diseases). Publicly insured AYAs were more likely than those with private insurance to be in the CVD (OR = 1.53, 95% CI = 1.18 to 1.98) and Multiple Conditions (OR = 2.17, 95% CI = 1.29 to 3.66) than the Low Morbidity group. AYAs with radiation were more likely to be in the Multiple Conditions (OR = 2.31, 95% CI = 1.41 to 3.78) and Thyroid (OR = 2.81, 95% CI = 2.20 to 3.58) groups. Hematopoietic cell transplantation was associated with Multiple Conditions (OR = 9.50, 95% CI = 5.82 to 15.50), CVD (OR = 3.82, 95% CI = 2.96 to 4.93), and Thyroid (OR = 2.86, 95% CI = 2.12 to 3.85) groups. Conclusions: While most AYA HL survivors were in the Low Morbidity group, those with public insurance or intense treatment may be at higher risk for multiple conditions.

  • Trastuzumab therapy and new-onset hypertension in adolescents and young adults with breast cancer

    by Renata Abrahão, Kathryn J. Ruddy, Cecile A. Laurent, Jessica Chubak, Eric C. Haupt, Ann M. Brunson, Erin E. Hahn, Chun R. Chao, Lisa M. Moy, Ted Wun, et al.

    Background Trastuzumab therapy carries a risk of acute cardiotoxicity, particularly when combined with anthracyclines. To date, no study has assessed hypertension as a potential long-term adverse effect of trastuzumab therapy in adolescent and young adult (AYA) cancer survivors. Methods We identified all female AYAs aged 15–39 years diagnosed with first primary invasive breast cancer between 2006 and 2020 in Kaiser Permanente Northern and Southern California, who survived at least 2 years post-diagnosis. Patients were categorized into two groups: those who received chemotherapy plus trastuzumab and those who received chemotherapy alone. We examined hypertension occurrence starting 2 years post-diagnosis, compared the 2–5-year cumulative incidence of hypertension between the trastuzumab and non-trastuzumab groups, and evaluated associated risk factors. Results Among 2382 female AYAs with breast cancer, 33.0% received trastuzumab. The 2–5-year cumulative incidence of hypertension did not differ between the trastuzumab (6.79%, 95% Confidence Interval [CI] 4.96–8.99%) and non-trastuzumab (7.85%, CI 6.41–9.48%) groups, p = 0.67. Trastuzumab was not associated with hypertension (hazard ratio (HR) = 1.01, CI 0.731–1.38) in multivariable analysis. Factors associated with higher hypertension included older age at diagnosis (35–39 vs. 15–34y), non-Hispanic Black or non-Hispanic Asian race/ethnicity (vs. non-Hispanic White), overweight or obesity (vs. underweight or normal weight), smoking, and endocrine therapy. History of diabetes and dyslipidemia showed borderline association with hypertension. Conclusion Trastuzumab was not associated with new-onset hypertension among AYA breast cancer survivors. However, sociodemographic and clinical factors significantly contributed to hypertension risk, highlighting the importance of interventions targeting modifiable risk factors.


  • Receipt of Guideline-Concordant Care Is Associated With Improved Survival in Patients With Osteosarcoma in California: A Population-Based Analysis

    by Renata Abrahão, Theresa H.M. Keegan, Frances B. Maguire, Qian Li, Marcio H. Malogolowkin, Samantha Wong, Steven W. Thorpe, Janai R. Carr-Asher, Amanda M. Midboe, R. Lor Randall, et al.

    PURPOSE: To examine the relationship between guideline-concordant care (GCC) on the basis of national clinical practice guidelines and survival in children (0-14 years), adolescents and young adults (AYAs, 15-39 years), and adults (40 years and older) with osteosarcoma, and to identify sociodemographic and clinical factors associated with receipt of GCC and survival. METHODS: We used data from the California Cancer Registry (CCR) on patients diagnosed with osteosarcoma during 2004-2019, with detailed treatment information extracted from the CCR text fields, including chemotherapy regimens. Multivariable logistic and Cox proportional hazard regression were used for statistical analyses. RESULTS: Of 1,716 patients, only 47% received GCC, with variation by age at diagnosis: 67% of children, 43% of AYAs, and 30% of adults. In multivariable models, patients who received part or all care ( v none) at specialized cancer centers were more likely to receive GCC. AYAs and adults were less likely to receive GCC than children (odds ratio [OR], 0.38 [95% CI, 0.30 to 0.50] and OR, 0.40 [95% CI, 0.28 to 0.56], respectively). In a model excluding adults, patients treated by pediatric ( v medical) oncologists were more likely to receive GCC (OR, 3.44 [95% CI, 2.40 to 4.94]). Patients with metastatic osteosarcoma at diagnosis who did not receive GCC had a greater hazard of death (hazard ratio [HR], 2.02 [95% CI, 1.55 to 2.63]) but no statistical differences were found in those diagnosed at earlier stages (HR, 1.15 [95% CI, 0.92 to 1.43]). CONCLUSION: GCC was associated with improved survival in patients with metastatic osteosarcoma in California. However, we found disparities in the delivery of GCC, highlighting the need for target interventions to improve delivery of GCC in this patient population.


  • Open Access

    Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry

    by Sara J. Schonfeld, Bryan Valcarcel, Christa L. Meyer, Bronwen E. Shaw, Rachel Phelan, J. Douglas Rizzo, Ann Brunson, Julianne J. P. Cooley, Renata Abrahão, Ted Wun, et al.

    Compared with the general population, hematopoietic cell transplantation (HCT) survivors are at elevated risk for developing solid subsequent neoplasms (SNs). The Center for International Blood and Marrow Transplant Research (CIBMTR) is a key resource for quantifying solid SN incidence following HCT, but the completeness of SN ascertainment is uncertain. Within a cohort of 18 450 CIBMTR patients linked to the California Cancer Registry (CCR), we evaluated the completeness of solid SN data reported to the CIBMTR from 1991 to 2018 to understand the implications of using CIBMTR data alone or combined with CCR data to quantify the burden of solid SNs after HCT. We estimated the cumulative incidence of developing a solid SN, accounting for the competing risk of death. Within the cohort, solid SNs were reported among 724 patients; 15.6% of these patients had an SN reported by CIBMTR only, 36.9% by CCR only, and 47.5% by both. The corresponding cumulative incidence of developing a solid SN at 10 years following a first HCT was 4.0% (95% confidence interval [CI], 3.5-4.4) according to CIBMTR data only, 5.3% (95% CI, 4.9-5.9) according to CCR data only, and 6.3% (95% CI, 5.7-6.8) according to both sources combined. The patterns were similar for allogeneic and autologous HCT recipients. Linking detailed HCT information from CIBMTR with comprehensive SN data from cancer registries provides an opportunity to optimize SN ascertainment for informing follow-up care practices and evaluating risk factors in the growing population of HCT survivors.


  • Open Access

    Association of IVCF use with mortality and intracranial hemorrhage in patients with selected cancers and brain metastasis

    by Renata Abrahão, Ann Brunson, Vaibhav Kumar, Anjlee Mahajan, Nigel S. Key, Theresa Keegan, Ted Wun